机译:IXAZOMIB-羟胺 - 低剂量地塞米松(ITD)诱导随后在新诊断的多发性骨髓瘤患者中与IXAZOMIB或安慰剂进行维持治疗,没有资格获得自体干细胞移植; 随机阶段II Hovon-126 / NMSG 21#13试验结果
Univ Amsterdam Med Ctr Canc Canc Amsterdam Dept Hematol Amsterdam Netherlands;
Oslo Univ Hosp KG Jebsen Ctr Cell Malignancies B Oslo Norway;
Erasmuc MC Canc Inst HOVON Data Ctr Dept Hematol Rotterdam Netherlands;
Albert Schweitzer Hosp Dept Internal Med Dordrecht Netherlands;
Vrije Univ Amsterdam Dept Hematol Canc Ctr Amsterdam Amsterdam UMC Amsterdam Netherlands;
St Olavs Hosp NTNU Dept Hematol Trondheim Norway;
Maasstad Ziekenhuis Rotterdam Netherlands;
Meander Med Ctr Dept Hematol Amersfoort Netherlands;
Forde Cent Hosp Forde Norway;
Helsinborg Hosp Helsingborg Sweden;
Dept Hematol Horsens Denmark;
Uddevalla Cent Hosp Uddevalle Sweden;
Ziekenhuis Rijnstate Dept Internal Med Arnhem Netherlands;
Aalborg Univ Hosp Aalborg Denmark;
Vrije Univ Amsterdam Med Ctr Dept Clin Genet Amsterdam Netherlands;
Radboud Univ Nijmegen Med Ctr Dept Hematol Nijmegen Netherlands;
Skane Univ Hosp Dept Hematol Lund Sweden;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Stavanger Univ Hosp Dept Hematol Stavanger Norway;
Erasmus MC Canc Inst Dept Hematol Rotterdam Netherlands;
Univ Southern Odense Univ Hosp Dept Hematol Odense Denmark;
机译:IXAZOMIB-羟胺 - 低剂量地塞米松(ITD)诱导随后在新诊断的多发性骨髓瘤患者中与IXAZOMIB或安慰剂进行维持治疗,没有资格获得自体干细胞移植; 随机阶段II Hovon-126 / NMSG 21#13试验结果
机译:序贯长春新碱,阿霉素,地塞米松(VAD),随后是硼替佐米,沙利度胺,地塞米松(VTD)的诱导,然后是自体干细胞移植的大剂量疗法和硼替佐米的合并疗法用于新诊断的多发性骨髓瘤:II期试验的结果
机译:序贯长春新碱,阿霉素,地塞米松(VAD),随后是硼替佐米,沙利度胺,地塞米松(VTD)的诱导,然后是自体干细胞移植的大剂量疗法和硼替佐米的合并疗法用于新诊断的多发性骨髓瘤:II期试验的结果
机译:逆转录病毒介导的人MDR-1转移的第1期试验在接受高剂量化疗和自体干细胞移植的患者中
机译:鱼油(二十碳五烯酸和二十二碳六烯酸)对急性肺损伤患者的肺和全身炎症的II期,随机,双盲,安慰剂对照试验。
机译:IXAZOMIB-羟胺胺 - 低剂量地塞米松诱导随后与新诊断的多发性骨髓瘤患者的IXAZOMIB或安慰剂进行维持治疗没有资格获得自体干细胞移植;随机阶段II Hovon-126 / NMSG的结果结果来自21.13试验
机译:环磷酰胺,沙利度胺和地塞米松作为新诊断为多发性骨髓瘤患者的自体干细胞移植的诱导疗法:MRC骨髓瘤IX随机试验结果